.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Chinese Patent Office
Novartis
Express Scripts
Teva
Cerilliant
Federal Trade Commission
McKesson
Chubb
Boehringer Ingelheim

Generated: July 24, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Vaginal device
Abstract:A vaginal device adapted for insertion and placement in the human vaginal cavity and subsequent removal therefrom for the administration of spermicide or a variety of medications such as anti-infectives, anti-inflammatories, estrogens, progestogens, and the like. When used as a contraceptive, the vaginal device covers/blocks the cervix, soaks up and traps sperm, and slowly releases a spermicide.
Inventor(s): Vorhauer; Bruce W. (Irvine, CA), Dobbie, Jr.; Thomas A. (Newport Beach, CA)
Assignee: VLI Corporation (Costa Mesa, CA)
Application Number:06/249,228
Patent Claims: 1. A vaginal device adapted for insertion and placement in the human vaginal cavity and subsequent removal therefrom, comprising:

a spermicide-foaming agent in a dry weight percentage of from about 10% to about 50%, and

a water-catalyzed foamed urethane polymer from which the spermicide is slowly released from the sponge during use.

2. The vaginal device of claim 1 including a drug for local delivery to the vaginal area, which drug is slowly released from the device during use.

3. The vaginal device of claim 1 including a non-toxic acid for lowering the pH of the device to between 4.0 and 5.0.

4. The vaginal device of claim 1 wherein the dry weight percentage of spermicide-foaming agent is at least 30%.

5. The vaginal device of claim 1 wherein the spermicide-foaming agent is nonylphenoxy polyethoxyethanol.

6. The vaginal device of claim 1 wherein the urethane polymer is water catalyzed from an isocyanate-capped hydrophilic polyoxyethylene polyol.

7. The vaginal device of claim 1 being in the shape of a flattened ball, one side of the device having a recess contoured to fit over the os of the cervix.

8. The vaginal device of claim 1 wherein the dry weight percentage of the spermicide-foaming agent is at least 30%.

9. A vaginal device adapted for insertion and placement in the human female vaginal cavity and subsequent removal therefrom, for the local administration of a drug, comprising:

a drug for local delivery to the vaginal area,

a foaming agent in a dry weight percentage of form about 10% to about 50%, and

a water-catalyzed foamed urethane polymer from which the drug is slowly released from the sponge during use.

10. The vaginal device of claim 9 wherein the drug is selected from the group consisting of anti-infectives, anti-inflammatories, estrogenic steroids, progestational agents, and prostaglandins.

11. The vaginal device of claim 9 being in the shape of a flattened ball, one side of the device having a recess contoured to fit over the os of the cervix.

12. A method for forming a vaginal device adapted for insertion and placement in the human vaginal cavity and subsequent removal therefrom; and

mixing from about 10% to 50% by dry weight of a foaming agent with a water-catalyzed, foam-forming urethane prepolymer and a dry agent for local delivery to the vaginal area; and

permitting the mixture of prepolymer, compound, and foaming agent to foam and form a stable, flexible, sponge-like structure from which the drug is slowly released from the sponge-like structure while in the vagina over a period of time.

13. The vaginal device of claim 12 being in the shape of a flattened ball, one side of the device having a recess contoured to fit over the os of the cervix.

14. The method of claim 12 wherein the foaming agent is a spermicide.

15. The method of claim 12 wherein the drug is selected from the group consisting of anti-infectives, anti-inflammatories, estrogenic steroids, progestational agents, and prostaglandins.

16. The method of claim 12 wherein the urethane prepolymer is an isocyanate-capped hydrophilic polyoxyethylene polyol.

17. A method for forming a vaginal device adapted for insertion and placement in the human vaginal cavity and subsequent removal therefrom, the device for the local administration of a spermicide, comprising:

mixing from about 10% to about 50% by dry weight of a spermicide-foaming agent with a water catalyzed, foam-forming urethane prepolymer; and

permitting the mixture of prepolymer and spermicide-foaming agent to foam and form a stable, flexible, sponge-like structure from which the spermicide-foaming agent is slowly released from the sponge structure while in the vagina over a period of time.

18. The method of claim 17 wherein the prepolymer is an isocyanate-capped hydrophilic polyoxyethylene polyol.

19. The method of claim 17 wherein the spermicide-foaming agent is nonylphenoxypoly ethoxyethanol.

20. The method of claim 17 wherein the dry weight percentage of spermicide-foaming agent is at least 30%.

21. The method of claim 17 wherein a drug intended for local delivery to the vaginal area is mixed with the spermicide-foaming agent and the prepolymer.

22. The method of claim 17 wherein a non-toxic acid is mixed with the spermicide-foaming agent and the prepolymer in quantity sufficient to lower the pH of the device to between about 4.0 and 5.5.

23. The method of claim 17 wherein the vaginal device is generally in the shape of a flattened ball, one side of the device having a recess contoured to fit over the os of the cervix.

24. A method of delivering an effective amount of a drug to the vaginal area comprising inserting into the human female vagina the device of claim 2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Medtronic
McKesson
Chinese Patent Office
Accenture
Queensland Health
Citi
Moodys
Merck
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot